Roche: Valcyte receives US approval for treatment of AIDS-related CMV retinitis
Oral drug with IV potency
Roche announced today that the U.S. food and Drug Administration (FDA) has approved Valcyte (valganciclovir) for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Valcyte is the oral pro-drug of Roche’s existing anti-CMV treatment, Cytovene (outside the US: Cymevene; ganciclovir) which is currently the most widely prescribed anti-CMV medication worldwide.
In a clinical study, Valcyte tablets were found to have comparable efficacy for induction therapy when compared to Cytovene-IV. The application for Valcyte received a priority review from the FDA, a designation reserved for treatments deemed to represent potentially major advances in healthcare.
“Since Cytovene was introduced in 1989, it has become the mainstay of anti-CMV treatment in patients with HIV/AIDS,” said Nick Coppard, Valcyte Project Leader, Roche. “We expect that Valcyte will replace and build upon Cytovene in the marketplace, because it offers comparable efficacy in a much more convenient dosing regimen for induction therapy.”
“CMV retinitis, which can lead to blindness, affects between 10 and 25 percent of people with the late stages of AIDS,” said Terje Anderson, executive director, National Association for People with AIDS, US. “It’s devastating to these patients to lose their eyesight at the same time they are fighting to survive. During the past few years, advances in treatments for HIV/AIDS have decreased the prevalence of opportunistic infections like CMV; however, there is still a need for convenient treatment regimens versusdrugs currently available for CMV retinitis,” Anderson added.
Studies in the prevention of CMV disease in solid organ transplantation recipients are underway and it is anticipated that applications for marketing authorisations for this indication will be filed in the second quarter, 2002.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Brazilian scientists reveal method of converting methane gas into liquid methanol - The conversion took place under ambient temperature and pressure conditions, which could enable methane, a potent greenhouse gas, to be used to produce fuel
Groundbreaking ceremony for the Pfeiffer Vacuum “Future Factory Asslar” - Expansion of the Asslar site
Covestro well on track - Group sales and EBITDA up significantly in the first quarter
University of Leicester researchers discover new fluorescent silicon nanoparticles - Research may ultimately track the uptake of drugs by the body's cells
Professor Matthias Driess Receives 2011 Wacker Silicone Award
3M and IBM to Develop New Types of Adhesives to Create 3D Semiconductors
Electron bubbles modelled from X-ray laser data - An international team of scientists uncovers a groundbreaking model for the effects of radiation in water systems
New Lillywomenshealth.com Web site Offers Women Valuable Resources in Just a Click!
August Wilhelm von Hofmann commemorative medal for the founders of the concept of green chemistry - Award ceremony for Paul Anastas and John Warner in Lisbon
DFG presents the 2006 MAK and BAT value list - Focus on health protection during pregnancy
Brenntag Nordic Oy - Vantaa, Finland
